MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1053/s0049-0172(03)00135-5

Медицинская библиотека · Seminars in arthritis and rheumatism · 2004

High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned.

Clements Philip J, Seibold James R, Furst Daniel E, Mayes Maureen, White Barbara, Wigley Fredrick, Weisman Michael D, Barr Water, Moreland Larry, Medsger Thomas A, Steen Virginia, Martin Richard W, Collier David, Weinstein Arthur, Lally Edward, Varga John, Weiner Steven R, Andrews Brian, Abeles Micha, Wong Weng Kee

Клиническое исследованиеСтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПоддержка службы здравоохранения СШАПеревод в очереди

Аннотация

OBJECTIVES

To review important findings, or lessons, that were learned about measures of response, design, conduct, and analysis of a randomized, controlled trial (RCT), even though the trial failed to demonstrate efficacy of d-penicillamine.

METHODS

One hundred thirty-four patients with early (< or =18 months), diffuse systemic sclerosis (SSc) were entered into an RCT (high-dose [822 mg daily] vs low-dose [120 mg every other day] D-penicillamine) and were followed up regularly for up to 4 years. Because analysis failed to show efficacy for D-penicillamine in early diffuse SSc, all data were pooled for additional secondary analyses.

RESULTS

This RCT showed that trials of potential disease-modifying interventions can be completed in SSc using the American College of Rheumatology guidelines. This RCT used an active control. After analysis, we were not able to tell whether either dose was effective or ineffective. That experience argues in favor of using placebo controls until such time as an active control can be found that truly modifies the disease. Skin score and the disability index of the Health Assessment Questionnaire (HAQ-DI) were valid predictors of outcome. Along with the physician global assessment, they also were valid measures of response.

CONCLUSIONS

Even in studies that are therapeutically "negative," careful evaluation of the data can examine other hypotheses and thereby provide important insights into other aspects of trial design, outcome measures, patient function, and trial conduct.

Для цитирования: Clements Philip J, Seibold James R, Furst Daniel E, Mayes Maureen, White Barbara, Wigley Fredrick, Weisman Michael D, Barr Water, Moreland Larry, Medsger Thomas A, Steen Virginia, Martin Richard W, Collier David, Weinstein Arthur, Lally Edward, Varga John, Weiner Steven R, Andrews Brian, Abeles Micha, Wong Weng Kee. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned.. Seminars in arthritis and rheumatism. 2004. DOI: 10.1053/s0049-0172(03)00135-5.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.